Editor's Correspondence |

Statin Use and Fracture Risk

John D. Seeger, PharmD, DrPH; Hyon K. Choi, MD, MPH
Arch Intern Med. 2002;162(20):2381. doi:.
Text Size: A A A
Published online


We were fascinated by the reduction in fracture risk with statin therapy reported by the Geelong Osteoporosis Study (odds ratio, 0.40; adjusted odds ratio, 0.45).1 These striking results are in concordance with 3 other published observational studies that found fracture risk reductions of similar magnitudes associated with statin exposure.24 However, they are in conflict with the results of a randomized clinical trial that found no association between pravastatin use and fracture risk.5 The explanation offered for the difference between these results is heterogeneity of effect on bone morphogenic protein-2 production between statins, and this contention is supported by in vitro data showing that pravastatin does not have the same effect as other statins on this biological marker.6 This intriguing hypothesis and its role in the divergence between the observational results and the pravastatin clinical trial results could be supported by presenting a subgroup analysis of effect according to specific statin, and we encourage the authors of the Geelong Osteoporosis Study to present such a subgroup analysis if data on specific statins are available. Since the other observational studies showing substantially reduced fracture risk with statin therapy included some pravastatin exposure, demonstrating that pravastatin is ineffective at preventing fracture would imply that the other statins are even more effective than the combined results would suggest.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview





Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles

Users' Guides to the Medical Literature
Clinical Scenario

Users' Guides to the Medical Literature
Statin Dosing and LDL Levels